250 related articles for article (PubMed ID: 22028826)
1. Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.
Moorwood C; Lozynska O; Suri N; Napper AD; Diamond SL; Khurana TS
PLoS One; 2011; 6(10):e26169. PubMed ID: 22028826
[TBL] [Abstract][Full Text] [Related]
2. Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening.
Moorwood C; Khurana TS
Expert Opin Drug Discov; 2013 May; 8(5):569-81. PubMed ID: 23473647
[TBL] [Abstract][Full Text] [Related]
3. A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation.
Moorwood C; Soni N; Patel G; Wilton SD; Khurana TS
J Biomol Screen; 2013 Apr; 18(4):400-6. PubMed ID: 23112083
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening identifies modulators of sarcospan that stabilize muscle cells and exhibit activity in the mouse model of Duchenne muscular dystrophy.
Shu C; Parfenova L; Mokhonova E; Collado JR; Damoiseaux R; Campagna J; John V; Crosbie RH
Skelet Muscle; 2020 Sep; 10(1):26. PubMed ID: 32948250
[TBL] [Abstract][Full Text] [Related]
5. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
Péladeau C; Jasmin BJ
Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
[TBL] [Abstract][Full Text] [Related]
6. Utrophin upregulation in Duchenne muscular dystrophy.
Hirst RC; McCullagh KJ; Davies KE
Acta Myol; 2005 Dec; 24(3):209-16. PubMed ID: 16629055
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy.
Ghosh S; Arshi MU; Ghosh S; Jash M; Sen S; Mamchaoui K; Bhattacharyya S; Rana NK; Ghosh S
J Med Chem; 2024 Jun; 67(11):9260-9276. PubMed ID: 38771158
[TBL] [Abstract][Full Text] [Related]
8. Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy.
Shu C; Kaxon-Rupp AN; Collado JR; Damoiseaux R; Crosbie RH
Skelet Muscle; 2019 Dec; 9(1):32. PubMed ID: 31831063
[TBL] [Abstract][Full Text] [Related]
9. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy.
Perkins KJ; Davies KE
FEBS Lett; 2018 Jun; 592(11):1856-1869. PubMed ID: 29772070
[TBL] [Abstract][Full Text] [Related]
10. A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy.
Burton EA; Tinsley JM; Holzfeind PJ; Rodrigues NR; Davies KE
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14025-30. PubMed ID: 10570192
[TBL] [Abstract][Full Text] [Related]
11. The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
Perkins KJ; Davies KE
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S78-89. PubMed ID: 12206801
[TBL] [Abstract][Full Text] [Related]
12. The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.
Perkins KJ; Burton EA; Davies KE
Nucleic Acids Res; 2001 Dec; 29(23):4843-50. PubMed ID: 11726694
[TBL] [Abstract][Full Text] [Related]
13. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?
Miura P; Jasmin BJ
Trends Mol Med; 2006 Mar; 12(3):122-9. PubMed ID: 16443393
[TBL] [Abstract][Full Text] [Related]
14. High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy.
Loro E; Sengupta K; Bogdanovich S; Whig K; Schultz DC; Huryn DM; Khurana TS
Sci Rep; 2020 Feb; 10(1):2132. PubMed ID: 32034254
[TBL] [Abstract][Full Text] [Related]
15. The utrophin promoter A drives high expression of the transgenic LacZ gene in liver, testis, colon, submandibular gland, and small intestine.
Takahashi J; Itoh Y; Fujimori K; Imamura M; Wakayama Y; Miyagoe-Suzuki Y; Takeda S
J Gene Med; 2005 Feb; 7(2):237-48. PubMed ID: 15538725
[TBL] [Abstract][Full Text] [Related]
16. Okadaic acid augments utrophin in myogenic cells.
Rodova M; Brownback K; Werle MJ
Neurosci Lett; 2004 Jun; 363(2):163-7. PubMed ID: 15172107
[TBL] [Abstract][Full Text] [Related]
17. Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles.
Péladeau C; Adam N; Bronicki LM; Coriati A; Thabet M; Al-Rewashdy H; Vanstone J; Mears A; Renaud JM; Holcik M; Jasmin BJ
Nat Commun; 2020 Apr; 11(1):1990. PubMed ID: 32332749
[TBL] [Abstract][Full Text] [Related]
18. Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening.
Soblechero-Martín P; Albiasu-Arteta E; Anton-Martinez A; de la Puente-Ovejero L; Garcia-Jimenez I; González-Iglesias G; Larrañaga-Aiestaran I; López-Martínez A; Poyatos-García J; Ruiz-Del-Yerro E; Gonzalez F; Arechavala-Gomeza V
Sci Rep; 2021 Sep; 11(1):18188. PubMed ID: 34521928
[TBL] [Abstract][Full Text] [Related]
19. UtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulation.
Onori A; Pisani C; Strimpakos G; Monaco L; Mattei E; Passananti C; Corbi N
BMC Mol Biol; 2013 Jan; 14():3. PubMed ID: 23363418
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ
Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
